Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856929 | 0.91 | OPRM1 (0.40) | ARMEN1KMT2AAMPD2CMA1 | |
| SCHEMBL291655 | 0.85 | MEN1 (0.40) | ARMEN1KMT2AAMPD2CMA1 | |
| SCHEMBL293635 | 0.84 | RECQL (0.40) | ARMEN1KMT2AAMPD2CMA1 | |
| SCHEMBL292960 | 0.83 | MEN1 (0.53) | ARMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL291850 | 0.78 | OPRM1 (0.49) | ARMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL291894 | 0.77 | MAPT (0.43) | MEN1KMT2AOPRM1HTR2BGRM5 | |
| SCHEMBL292131 | 0.76 | AR (0.43) | ARMEN1KMT2ACMA1GRM5 | |
| SCHEMBL292608 | 0.75 | AR (0.39) | AROPRM1OPRL1GRM5HTR7 | |
| SCHEMBL291498 | 0.75 | AR (0.42) | ARMEN1KMT2AAMPD2OPRM1 | |
| SCHEMBL292093 | 0.74 | AR (0.41) | ARMEN1KMT2AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | AR 329/4885MEN1 869/4885KMT2A 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.